Connect with us

Chronic Illness

Unlocking the Secrets of Kidney Scarring: A Precision Medicine Approach to Prevent Chronic Kidney Disease Progression

Researchers have identified type 5 collagen as a key factor in kidney fibrosis, revealing its potential as a biomarker to predict chronic kidney disease progression. A repurposed anti-cancer drug, Cilengitide, was found to reduce kidney scarring and slow disease progression in preclinical models, suggesting a possible precision medicine approach for high-risk patients. The team now seeks to develop a blood test to measure type 5 collagen levels, which could help identify patients at greater risk for kidney failure and guide targeted treatment strategies.

Avatar photo

Published

on

Researchers at the University of California, Los Angeles (UCLA) have made a groundbreaking discovery that could revolutionize the treatment of chronic kidney disease (CKD). A study published in Science Translational Medicine has uncovered a critical factor that determines how much scarring occurs following kidney injury, leading scientists to identify a potential precision medicine approach to prevent CKD progression.

The researchers, led by Dr. Arjun Deb, found that type 5 collagen – a minor component of scar tissue – plays a crucial role in maintaining the structure and function of scar tissue. They discovered that differences in type 5 collagen expression help explain why some people develop more extensive kidney scarring than others.

This breakthrough has significant implications for the treatment of CKD, which affects over 800 million people worldwide. Currently, there are no therapies that directly target or reverse fibrosis, a process that impairs the kidneys’ ability to filter toxins from the blood and reabsorb water, often leading to kidney failure.

The study involved analyzing data from the UK Biobank, a long-term study tracking more than 1.5 million people. The researchers found that expression of Col5a1, the gene encoding type 5 collagen, strongly correlated with the risk of developing CKD over the course of a decade.

A series of experiments in mouse models confirmed these findings: Mice with low Col5a1 developed more severe fibrosis and progressed more rapidly to kidney failure following kidney injury. As with humans, type 5 collagen was playing a crucial role in maintaining the structure and function of scar tissue.

The researchers identified a potential solution in Cilengitide, a drug that disrupts integrin signaling. They found that treating animals with decreased type 5 collagen with Cilengitide significantly reduced kidney fibrosis and slowed disease progression. Notably, it had no effect in mice with normal Col5a1 expression, highlighting its potential as a targeted therapy for individuals at risk of rapid disease progression.

This presents an exciting opportunity to potentially repurpose this drug, which was already deemed safe by the FDA, for a completely different indication.

The researchers are now working to establish a blood test to measure Col5a1 levels in human patients with CKD to establish a clinical threshold for identifying at-risk individuals. If validated, this biomarker could be used to guide treatment decisions, pinpointing patients who could benefit from this targeted approach to slowing disease progression.

Beyond CKD, the researchers are also investigating whether the same mechanisms contribute to fibrosis in the liver and blood vessels, where scarring is a major driver of disease.

The use of Cilengitide has not been tested in humans as a treatment for excessive scarring and has not been approved by the Food and Drug Administration as safe and effective for this use. This novel therapeutic approach is covered by a patent application filed by the UCLA Technology Development Group on behalf of the Regents of the University of California.

The study’s findings have significant implications for the treatment of CKD, and further research is needed to validate these results and explore their potential applications in humans.

Animal Learning and Intelligence

Harnessing the Power of Nature: How Black Tea and Berries Can Promote Healthy Aging

Higher intakes of black tea, berries, citrus fruits and apples could help to promote healthy aging, new research has found.

Avatar photo

Published

on

As we age, our bodies undergo various changes that can impact our physical and mental well-being. While some of these changes are inevitable, research suggests that incorporating certain foods into our diet can help promote healthy aging.

A recent study conducted by researchers from Edith Cowan University, Queen’s University Belfast, and Harvard T.H. Chan School of Public Health found that consuming higher intakes of black tea, berries, citrus fruits, and apples could lower the risk of key components of unhealthy aging, including frailty, impaired physical function, and poor mental health.

The study analyzed data from 62,743 women and 23,687 men over a period of 24 years. The findings revealed that women with the highest flavonoid intakes had a 15% lower risk of frailty, a 12% lower risk of impaired physical function, and a 12% lower risk of poor mental health compared to those with the lowest intakes.

While fewer associations were observed in men, higher flavonoid intake was still linked to a lower risk of poor mental health. The researchers suggested that regularly consuming flavonoid-rich foods could support healthier aging by reducing the risk of frailty, physical decline, and poor mental health.

The study’s lead author, Dr. Nicola Bondonno from Edith Cowan University, emphasized the importance of medical research in promoting healthy aging. “Our goal is not just to help people live longer but to ensure they stay healthy for as long as possible,” she said.

Professor Aedin Cassidy from Queen’s University Belfast added that flavonoids have been shown to reduce oxidative stress and inflammation, supporting blood vessel health, and even helping to maintain skeletal muscle mass – all of which are crucial for preventing frailty and maintaining physical function and mental health as we age.

The researchers noted that incorporating three servings of flavonoid-rich food into one’s diet could lead to a 6% to 11% lower risk across all three aging outcomes in females, and a 15% lower risk of poor mental health in males. This highlights the potential for simple dietary modifications to impact overall quality of life and contribute to the optimisation of healthy aging.

Overall, this study underscores the importance of incorporating flavonoid-rich foods into our diet to promote healthier aging. As Professor Eric Rimm from Harvard T.H. Chan School of Public Health noted, “These findings underscore the potential for simple dietary modifications to impact overall quality of life and contribute to the optimisation of healthy aging.”

Continue Reading

Cholesterol

Unlocking the Secrets of Human Longevity: A Decade of Discovery

Researchers participating in the Cilento Initiative on Aging Outcomes or CIAO study will gather in Acciaroli (Pollica-Cilento) Salerno, Italy to review a decade of work and plan their next steps. Launched in 2016, the CIAO study seeks to identify key factors (biological, psychological and social) that promote healthy aging and extreme longevity.

Avatar photo

Published

on

The Cilento Initiative on Aging Outcomes (CIAO) study has been a decade in the making, and this month, researchers will gather in Acciaroli, Italy to review their progress and plan their next steps. Launched in 2016, the CIAO study seeks to identify key factors that promote healthy aging and extreme longevity.

The region of Cilento in southern Italy is home to a remarkable 300 residents who are over 100 years old and in robust health. This area was also the original source of research for Ancel Keys, the American physiologist who studied the influence of diet on health and promoted the benefits of the Mediterranean diet.

Scientists hope to reveal the longevity secrets of the Cilento region by using an array of tools to measure metabolomics, biomes, cognitive dysfunction, and protein biomarkers for risk of heart disease, Alzheimer’s, kidney disease, and cancer. They will also conduct psychological, social, and lifestyle surveys to gain a more comprehensive understanding.

“There is no single secret to living a long, healthy life,” said Salvatore Di Somma, MD, the study’s lead Italian investigator. “It is many secrets, most of which we are only beginning to understand and more importantly, learn how they might be applied to the well-being of everybody.”

The CIAO study is a multi-institution collaboration that includes Sanford Burnham Prebys, an independent nonprofit biomedical research institute in San Diego, the Sanford Stem Cell Institute at University of California San Diego, University La Sapienza in Rome, and Great Health Science.

A symposium will take place on May 22-23, featuring scientists describing their work and findings. The event is titled “CIAO Study: A decade of science on healthy aging, stem cells, and the revealed secrets of longevity.” Understanding how we age and how we might age better is a timeless pursuit, said David Brenner, MD, president and CEO of Sanford Burnham Prebys.

Current CIAO projects are leveraging genetic, epigenetic, transcriptomic, metabolic, proteomic, and environmental analyses to identify key contributors to extreme longevity. Researchers are using induced pluripotent stem cell (iPSC) derived from the centenarians to model age-related and metabolic stresses in human 3D organoids.

“This study will provide new insights into the development of regenerative medicine strategies for promoting healthy aging and treating age-related conditions,” said Tatiana Kisseleva, MD, PhD, professor of surgery at UC San Diego School of Medicine. Preliminary findings are expected to be presented at the symposium.

Continue Reading

Chronic Illness

The Immune System’s Hidden Role in Mental Health Conditions

Depression, schizophrenia and other mental health conditions affect 1 in 4 people in their lifetime, but mechanisms underlying these conditions are poorly understood. New research has linked the body’s immune response with schizophrenia, Alzheimer’s disease, depression, and bipolar disorder. The study demonstrates mental health conditions might be affected by the whole body as well as changes in the brain. The findings could pave the way for better treatments of some mental health conditions.

Avatar photo

Published

on

The world of psychology has long been dominated by the idea that mental health conditions such as depression, schizophrenia, and bipolar disorder are solely the result of imbalances in brain chemistry. However, new research suggests that there is more to it than meets the eye – or rather, more to the body. A groundbreaking study led by researchers at the University of Bristol has made a startling discovery: the immune system plays a significant role in these conditions.

The study, which was published in a recent scientific paper, used a computational approach called Mendelian randomization to examine the relationship between immunological proteins and seven neuropsychiatric conditions, including depression, anxiety, schizophrenia, bipolar disorder, Alzheimer’s disease, autism, and ADHD. The researchers found that 29 immune response-related proteins were potentially involved in these conditions.

One of the most significant findings was that overactivity of the immune system could contribute to the cause of mental health conditions. This challenges the traditional view that depression and schizophrenia are solely caused by imbalances in brain chemicals such as serotonin and dopamine. In fact, the study suggests that a new paradigm is needed – one where mental health conditions are viewed as affecting the whole person, not just the mind.

The implications of this research are profound. It could lead to the development of novel therapeutics for mental health conditions by targeting immune response-related proteins. Furthermore, it challenges the centuries-old dichotomy between body and mind, suggesting that we should consider depression and schizophrenia as conditions affecting the whole person.

As Professor Golam Khandaker, one of the researchers involved in the study, noted: “Our study demonstrates that inflammation in the brain and the body might influence the risk of mental health conditions.” The next step is to further evaluate causality, understand precise mechanisms from inflammation to symptoms, and therapeutic potential – does modulating immune pathways improve symptoms of these conditions?

This research has far-reaching implications for our understanding of mental health conditions and their treatment. It highlights the importance of considering the immune system as a vital component in understanding and addressing these disorders.

Continue Reading

Trending